| Host |
Rabbit |
| Klon |
ZR400 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Human brain, lung adenocarcinoma, or primary glioblastoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
| Lokalisation |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
1 ml |
Concentrate |
RUO |
Z2756RL-R |
-
|
| Host |
Rabbit |
| Klon |
ZR400 |
| Format |
reasy-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Human brain, lung adenocarcinoma, or primary glioblastoma |
| Verdünnung |
--- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
| Lokalisation |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
7 ml |
reasy-to-use |
RUO |
Z2756RP-R |
-
|
| Host |
Rabbit |
| Klon |
ZR400 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Human brain, lung adenocarcinoma, or primary glioblastoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
| Lokalisation |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
0.5 ml |
Concentrate |
RUO |
Z2756RS-R |
-
|
| Host |
Rabbit |
| Klon |
ZR400 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
HIER or PIER |
| Positivkontrolle |
Human brain, lung adenocarcinoma, or primary glioblastoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to the cytoplasmic domain of human ROS1 protein |
| Lokalisation |
cell surface |
ROS1
|
Zeta Corporation |
ZR400 |
0.1 ml |
Concentrate |
RUO |
Z2756RT-R |
-
|
| Host |
Mouse |
| Klon |
9H8 |
| Format |
Concentrate |
| Methode |
F, P, IP, IF, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
RPA (p34) (Replication Protein A)
|
Diagnostic Biosystems |
9H8 |
1 ml |
Concentrate |
CE/IVD |
MOB329 |
-
|
| Host |
Mouse |
| Klon |
9H8 |
| Format |
Concentrate |
| Methode |
F, P, IP, IF, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
RPA (p34) (Replication Protein A)
|
Diagnostic Biosystems |
9H8 |
0.1 ml |
Concentrate |
CE/IVD |
MOB329-01 |
-
|
| Host |
Mouse |
| Klon |
9H8 |
| Format |
Concentrate |
| Methode |
F, P, IP, IF, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Nucleus |
RPA (p34) (Replication Protein A)
|
Diagnostic Biosystems |
9H8 |
0.5 ml |
Concentrate |
CE/IVD |
MOB329-05 |
-
|
| Host |
Mouse |
| Klon |
4C4.9 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
1:150 - 1:300 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Purified bovine brain S100 p |
| Lokalisation |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
1ml |
Concentrate |
CE/IVD |
Z2055ML |
-
|
| Host |
Mouse |
| Klon |
4C4.9 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
- |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Purified bovine brain S100 p |
| Lokalisation |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
7 ml |
Ready-to-use |
CE/IVD |
Z2055MP |
-
|
| Host |
Mouse |
| Klon |
4C4.9 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
1:150 - 1:300 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Purified bovine brain S100 p |
| Lokalisation |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
0.5 ml |
Concentrate |
CE/IVD |
Z2055MS |
-
|
| Host |
Mouse |
| Klon |
4C4.9 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Melanoma. |
| Verdünnung |
1:150 - 1:300 |
| Isotyp |
IgG2a /κ |
| Verdünnung |
Purified bovine brain S100 p |
| Lokalisation |
Cytoplasm and Nucleus |
S-100
|
Zeta Corporation |
4C4.9 |
0.1 ml |
Concentrate |
CE/IVD |
Z2055MT |
-
|
| Host |
Rabbit |
| Klon |
SP50 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide derived from the region of human S6 ribosomal that contains phosphorylated serines 235 and 236 |
| Lokalisation |
Cytoplasm |
S6 Ribosomal (phospho S235/236)
|
Zytomed Systems GmbH |
SP50 |
1 ml |
Concentrate |
RUO |
519-3504 |
-
|
| Host |
Mouse |
| Klon |
SH-B1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin or Fast Enzyme |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
1 ml |
Concentrate |
CE/IVD |
MOB111 |
-
|
| Host |
Mouse |
| Klon |
SH-B1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin or Fast Enzyme |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB111-01 |
-
|
| Host |
Mouse |
| Klon |
SH-B1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin or Fast Enzyme |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB111-05 |
-
|
| Host |
Mouse |
| Klon |
4C4.9 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse |
| Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
4C4.9 |
1 ml |
Concentrate |
CE/IVD |
MOB377 |
-
|
| Host |
Mouse |
| Klon |
4C4.9 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse |
| Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
4C4.9 |
0.1 ml |
Concentrate |
CE/IVD |
MOB377-01 |
-
|
| Host |
Mouse |
| Klon |
4C4.9 |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse |
| Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
4C4.9 |
0.5 ml |
Concentrate |
CE/IVD |
MOB377-05 |
-
|
| Host |
Mouse |
| Klon |
SH-B1 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Trypsin or Fast Enzyme |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
SH-B1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM088 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Trypsin or Pepsin (optional) |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR008 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin or Pepsin (optional) |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP035 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin or Pepsin (optional) |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP035-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Trypsin or Pepsin (optional) |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:50 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP035-05 |
-
|
| Host |
Rabbit |
| Klon |
ZR115 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon cancer |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to C-terminal of human S100P protein |
| Lokalisation |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
1 ml |
Concentrate |
CE/IVD |
Z2419RL |
-
|
| Host |
Rabbit |
| Klon |
ZR115 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon cancer |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to C-terminal of human S100P protein |
| Lokalisation |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
7 ml |
Concentrate |
CE/IVD |
Z2419RP |
-
|
| Host |
Rabbit |
| Klon |
ZR115 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon cancer |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to C-terminal of human S100P protein |
| Lokalisation |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
0.5 ml |
Concentrate |
CE/IVD |
Z2419RS |
-
|
| Host |
Rabbit |
| Klon |
ZR115 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon cancer |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to C-terminal of human S100P protein |
| Lokalisation |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
0.1 ml |
Concentrate |
CE/IVD |
Z2419RT |
-
|
| Host |
Sheep |
| Klon |
Polyclonal |
| Format |
Purified |
| Methode |
Double Diffusion, Immunelectrophoresis |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Purified human amylase (Type XIII-A) from saliva |
Salivary Amylase
|
Zytomed Systems GmbH |
Polyclonal |
100 µl |
Purified |
RUO |
A12-6124 |
-
|
| Host |
Mouse |
| Klon |
6E3 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Seminoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
SALL4 (partial recombinant protein with GST tag) |
| Lokalisation |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
1 ml |
Concentrate |
CE/IVD |
MOB591 |
-
|
| Host |
Mouse |
| Klon |
6E3 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Seminoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
SALL4 (partial recombinant protein with GST tag) |
| Lokalisation |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB591-01 |
-
|
| Host |
Mouse |
| Klon |
6E3 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Seminoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
SALL4 (partial recombinant protein with GST tag) |
| Lokalisation |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB591-05 |
-
|
| Host |
Mouse |
| Klon |
monoclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Seminoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Recombinant protein corresponding to the amino acid residues 954 to 10954 of human SALL4 protein |
| Lokalisation |
Nucleus |
SALL4
|
Zytomed Systems GmbH |
monoclonal |
0.5 ml |
Concentrate |
RUO |
MSK079-05 |
-
|
| Host |
Mouse |
| Klon |
6E3 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Seminoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
SALL4 (partial recombinant protein with GST tag) |
| Lokalisation |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM591 |
-
|
| Host |
Rabbit |
| Klon |
SP281 |
| Format |
Concentrate |
| Reaktivität |
MS |
| Methode |
P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon, colon adenocarcinoms |
| Verdünnung |
1:100 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide derived from the C-terminus of human SATB2 protein |
| Lokalisation |
Nucleus |
SATB2
|
Zytomed Systems GmbH |
SP281 |
1 ml |
Concentrate |
RUO |
519-5814 |
-
|
| Host |
Mouse |
| Klon |
SATBA4B10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colorectal adenocarcinma |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Verdünnung |
Recombinant protein fragment corresponding to the C-terminus of human SATB2 |
| Lokalisation |
Nucleus |
SATB2
|
Zytomed Systems GmbH |
SATBA4B10 |
16 ml |
Ready-to-use |
RUO |
BMS068 |
-
|
| Host |
Mouse |
| Klon |
SATBA4B10 |
| Format |
Ready-to-use |
| Methode |
F, P, WB, IP |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Verdünnung |
Recombinant fragment of the C-terminal of human SATB2 |
| Lokalisation |
Nucleus |
SATB2
|
Zytomed Systems GmbH |
SATBA4B10 |
6 ml |
Ready-to-use |
RUO |
MSG101 |
-
|
| Host |
Mouse |
| Klon |
SATBA4B10 |
| Format |
Concentrate |
| Methode |
F, P, WB, IP |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Verdünnung |
Recombinant fragment of the C-terminal of human SATB2 |
| Lokalisation |
Nucleus |
SATB2
|
Zytomed Systems GmbH |
SATBA4B10 |
0.5 ml |
Concentrate |
RUO |
MSK101-05 |
-
|
| Host |
Rabbit |
| Klon |
EP281 |
| Format |
Concentrate |
| Vorbehandlung |
EDTA pH8 |
| Positivkontrolle |
Colon carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to human SATB2 |
| Lokalisation |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
1 ml |
Concentrate |
CE/IVD |
RMAB112 |
-
|
| Host |
Rabbit |
| Klon |
EP281 |
| Format |
Concentrate |
| Vorbehandlung |
EDTA pH8 |
| Positivkontrolle |
Colon carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to human SATB2 |
| Lokalisation |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB112-01 |
-
|
| Host |
Rabbit |
| Klon |
EP281 |
| Format |
Concentrate |
| Vorbehandlung |
EDTA pH8 |
| Positivkontrolle |
Colon carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to human SATB2 |
| Lokalisation |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB112-05 |
-
|
| Host |
Rabbit |
| Klon |
EP281 |
| Format |
r-t-u |
| Vorbehandlung |
EDTA pH8 |
| Positivkontrolle |
Colon carcinoma |
| Verdünnung |
gebrauchsfertig |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to human SATB2 |
| Lokalisation |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
6 ml |
r-t-u |
CE/IVD |
RMPD112 |
-
|
| Host |
Rabbit |
| Klon |
ZR167 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon, colon carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa150-350) of human SATB2 protein |
| Lokalisation |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
1 ml |
Concentrate |
CE/IVD |
Z2479RL |
-
|
| Host |
Rabbit |
| Klon |
ZR167 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon, colon carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa150-350) of human SATB2 protein |
| Lokalisation |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
7 ml |
Ready-to-use |
CE/IVD |
Z2479RP |
-
|
| Host |
Rabbit |
| Klon |
ZR167 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon, colon carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa150-350) of human SATB2 protein |
| Lokalisation |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
0.5 ml |
Concentrate |
CE/IVD |
Z2479RS |
-
|
| Host |
Rabbit |
| Klon |
ZR167 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon, colon carcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment (around aa150-350) of human SATB2 protein |
| Lokalisation |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
0.1 ml |
Concentrate |
CE/IVD |
Z2479RT |
-
|
| Host |
Rabbit |
| Klon |
ZR339 |
| Format |
Concentrate |
| Methode |
IHC, FFPE |
| Vorbehandlung |
Citrate o EDTA |
| Positivkontrolle |
RCC, paraganglioma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
| Lokalisation |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
1.0 ml |
Concentrate |
CE/IVD |
Z2645RL |
-
|
| Host |
Rabbit |
| Klon |
ZR339 |
| Format |
ready-to-use |
| Methode |
IHC, FFPE |
| Vorbehandlung |
Citrate o EDTA |
| Positivkontrolle |
RCC, Paraganglioma |
| Verdünnung |
--- |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
| Lokalisation |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
7 ml |
ready-to-use |
CE/IVD |
Z2645RP |
-
|
| Host |
Rabbit |
| Klon |
ZR339 |
| Format |
Concentrate |
| Methode |
IHC, FFPE |
| Vorbehandlung |
Citrate o EDTA |
| Positivkontrolle |
RCC, paraganglioma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
| Lokalisation |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
0.5 ml |
Concentrate |
CE/IVD |
Z2645RS |
-
|
| Host |
Rabbit |
| Klon |
ZR339 |
| Format |
Concentrate |
| Methode |
IHC, FFPE |
| Vorbehandlung |
Citrate o EDTA |
| Positivkontrolle |
RCC, paraganglioma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
| Lokalisation |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
0.1 ml |
Concentrate |
CE/IVD |
Z2645RT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast (Carcinoma) |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to internal region of human smad3. |
| Lokalisation |
Nuclear (mainly) |
SMAD3
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
519-11254 |
-
|